Several modified anti-CD38 mAbs, such as daratumumab, isatuximab, and MOR202, have been developed to treat CD38+ RR MM via mechanisms of action including Fc-dependent immune-effector manner and immunomodulatory effects [161, 163, 164]. The gene discussed is CD38; the disease is Miyoshi myopathy.